EMS-CHEMIE HOLDING Valuation
Is EMSN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of EMSN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: EMSN (CHF692.5) is trading above our estimate of fair value (CHF657.95)
Significantly Below Fair Value: EMSN is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for EMSN?
Other financial metrics that can be useful for relative valuation.
What is EMSN's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | CHF 16.20b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 7.5x |
Enterprise Value/EBITDA | 28.8x |
PEG Ratio | 3.9x |
Price to Earnings Ratio vs Peers
How does EMSN's PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 32x | ||
GIVN Givaudan | 39x | 5.3% | CHF 40.3b |
SIKA Sika | 34.3x | 11.5% | CHF 42.1b |
CLN Clariant | 35.5x | 30.2% | CHF 4.2b |
GURN Gurit Holding | 19.1x | 38.5% | CHF 142.6m |
EMSN EMS-CHEMIE HOLDING | 35.1x | 9.1% | CHF 16.2b |
Price-To-Earnings vs Peers: EMSN is expensive based on its Price-To-Earnings Ratio (35.1x) compared to the peer average (32x).
Price to Earnings Ratio vs Industry
How does EMSN's PE Ratio compare vs other companies in the European Chemicals Industry?
Price-To-Earnings vs Industry: EMSN is expensive based on its Price-To-Earnings Ratio (35.1x) compared to the European Chemicals industry average (17.5x).
Price to Earnings Ratio vs Fair Ratio
What is EMSN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 35.1x |
Fair PE Ratio | 20.4x |
Price-To-Earnings vs Fair Ratio: EMSN is expensive based on its Price-To-Earnings Ratio (35.1x) compared to the estimated Fair Price-To-Earnings Ratio (20.4x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | CHF 692.50 | CHF 730.63 +5.5% | 11.4% | CHF 900.00 | CHF 633.00 | n/a | 8 |
Aug ’25 | CHF 733.50 | CHF 730.63 -0.4% | 11.4% | CHF 900.00 | CHF 633.00 | n/a | 8 |
Jul ’25 | CHF 739.50 | CHF 675.00 -8.7% | 10.5% | CHF 800.00 | CHF 580.00 | n/a | 7 |
Jun ’25 | CHF 744.00 | CHF 667.14 -10.3% | 9.6% | CHF 800.00 | CHF 580.00 | n/a | 7 |
May ’25 | CHF 737.00 | CHF 664.29 -9.9% | 9.8% | CHF 800.00 | CHF 580.00 | n/a | 7 |
Apr ’25 | CHF 692.00 | CHF 664.29 -4.0% | 9.8% | CHF 800.00 | CHF 580.00 | n/a | 7 |
Mar ’25 | CHF 624.00 | CHF 655.71 +5.1% | 12.2% | CHF 800.00 | CHF 547.00 | n/a | 7 |
Feb ’25 | CHF 658.00 | CHF 657.14 -0.1% | 12.5% | CHF 800.00 | CHF 547.00 | n/a | 7 |
Jan ’25 | CHF 681.00 | CHF 657.14 -3.5% | 12.5% | CHF 800.00 | CHF 547.00 | n/a | 7 |
Dec ’24 | CHF 621.50 | CHF 657.14 +5.7% | 12.5% | CHF 800.00 | CHF 547.00 | n/a | 7 |
Nov ’24 | CHF 621.50 | CHF 704.57 +13.4% | 11.4% | CHF 850.00 | CHF 613.00 | n/a | 7 |
Oct ’24 | CHF 623.00 | CHF 704.57 +13.1% | 11.4% | CHF 850.00 | CHF 613.00 | n/a | 7 |
Sep ’24 | CHF 665.50 | CHF 700.29 +5.2% | 11.6% | CHF 850.00 | CHF 613.00 | CHF 711.50 | 7 |
Aug ’24 | CHF 726.00 | CHF 700.71 -3.5% | 11.5% | CHF 850.00 | CHF 613.00 | CHF 733.50 | 7 |
Jul ’24 | CHF 677.00 | CHF 712.86 +5.3% | 14.3% | CHF 900.00 | CHF 560.00 | CHF 739.50 | 7 |
Jun ’24 | CHF 704.50 | CHF 716.43 +1.7% | 14.5% | CHF 900.00 | CHF 575.00 | CHF 744.00 | 7 |
May ’24 | CHF 731.50 | CHF 720.71 -1.5% | 14.5% | CHF 900.00 | CHF 575.00 | CHF 737.00 | 7 |
Apr ’24 | CHF 754.00 | CHF 722.57 -4.2% | 14.4% | CHF 900.00 | CHF 575.00 | CHF 692.00 | 7 |
Mar ’24 | CHF 717.00 | CHF 702.50 -2.0% | 15.1% | CHF 900.00 | CHF 575.00 | CHF 624.00 | 6 |
Feb ’24 | CHF 683.00 | CHF 684.17 +0.2% | 16.6% | CHF 900.00 | CHF 575.00 | CHF 658.00 | 6 |
Jan ’24 | CHF 626.00 | CHF 684.17 +9.3% | 16.6% | CHF 900.00 | CHF 575.00 | CHF 681.00 | 6 |
Dec ’23 | CHF 666.50 | CHF 700.83 +5.2% | 17.8% | CHF 900.00 | CHF 575.00 | CHF 621.50 | 6 |
Nov ’23 | CHF 617.50 | CHF 756.57 +22.5% | 19.4% | CHF 1,001.00 | CHF 575.00 | CHF 621.50 | 7 |
Oct ’23 | CHF 628.50 | CHF 902.29 +43.6% | 10.7% | CHF 1,001.00 | CHF 740.00 | CHF 623.00 | 7 |
Sep ’23 | CHF 669.00 | CHF 925.14 +38.3% | 9.8% | CHF 1,001.00 | CHF 740.00 | CHF 665.50 | 7 |
Analyst Forecast: Target price is less than 20% higher than the current share price.